Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?

Acta Oncologica

Volumn 44, Issue 2, 2005, Pages 155-160

  Pentheroudakis, George ^a   Briasoulis, Evangelos ^a   Karavassilis, Vassilis ^a   Fountzilas, George ^b   Xeros, Nikolaos ^c   Samelis, George ^d   Samantas, Epaminondas ^e   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

^e General Oncology Hospital Agioi Anargyroi   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CARCINOMA; CARCINOMATOUS PERITONITIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR REGRESSION; UNDIFFERENTIATED CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; GREECE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 17144371296     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510029554     Document Type: Article

References (19)

1. Levi F, Te VC, Erler G, et al. Epidemiology of unknown primary tumours. Eur J Cancer 2002;38:1810-2.
2. Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist 1997;2(3):142-52.
3. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
4. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 1986;142:547-53.
5. Dalrymple JC, Bannatyne P, Russel P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989;64:110-5.
6. Stewart J, Tattersall M, Woods R, et al. Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. Br Med J 1979;1:1530-3.
7. Richardson RL, Schumacher R, Oldham RK, et al. The unrecognized extragonadal germ cell syndrome. Ann Intern Med 1981;94:181-9.
8. Ransom DT, Patel SR, Keeney GL, et al. Papillary serous carcinoma of the peritoneum. Cancer 1990;66:1091-4.
9. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 2000;18:3101-7.
10. Pavlidis N, Kosmidis P, Skarlos D, et al. Subsets of tumours responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group study. Ann Oncol 1992;3:631-4.
11. Briasoulis E, Tsavaris N, Fountzilas G, et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Cooperative Oncology Group phase II study. Oncol 1998;55:426-30.
12. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-5.
13. Chen KT, Flam MS. Peritoneal papillary serous carcinoma with long-term survival. Cancer 1986;58:1371-3.
14. Alberts AS, Falkson G, Falkson HC, Van der Merwe MP. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol 1989;17:188-92.
15. Greco FA, Hainsworth JD. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy. Semin Oncol 1994;5(Suppl 12):77-82.
16. Berek JS, Taylor PT, Gordon AN, Schultes BC, Whiteside TL, Nicodemus CF. Randomized placebo-controlled study of oregovomab for consolidation of clinical remission in patients with ovarian cancer: prolonged disease-free survival in optimal chemosensitive patients. Proc Am Soc Clin Oncol 2003;22:165 (Abstract 660).
17. Markman M, Liu PY, Wilczynski S, Monk BJ, Copeland L, Alberts D. Phase III randomized trial of twelve versus three months of single agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum-paclitaxel based chemotherapy. A SWOG/GOG trial. Program of the 33rd Ann Meeting of the Soc Gynecol Oncologists, 16-20 March 2002, Miami, FL (Abstract 1).
18. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272-80.
19. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679-83.